mobilemenuClose menu

The European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF) is a non-profit organization that brings together European national patient associations committed to defending their vision of equal access to treatment and care for all IPF patients, regardless of geography, socio-economic status or age. Our common view has encouraged us to officially establish the first European IPF and other related disorders federation in July 2016.

Our commitment and ambition are grounded in one of our key achievements: the development of the European IPF Charter, which was launched in the European Parliament in September 2014. The Charter lays down the rights of IPF patients and concrete policy recommendations that, if adopted, would ensure improvements in patients’ quality of life whilst supporting efforts to find a cure.

We aim to serve as a trusted resource for the IPF community by raising awareness, providing disease education, advancing care, and supporting research for IPF whilst defending the interests of IPF patients at European level. We fight for equal access to treatment, information and ensuring exchange of information between national patient groups.

Each year, during IPF World Week, IPF patient associations across the world join forces to raise awareness of IPF, call for better access to care, and bring hope to those living with the disease.

Our Aim

EU-IPFF defends the rights of patients across Europe* by advocating for an immediate and sustainable improvement of the quality of life and survival time of those with progressive Pulmonary Fibrosis (PF) whilst also promoting awareness of Interstitial Lung Diseases {ILDs) generally and defending the interests of PF patients from across the continent at a pan-European level

*according to WHO definition

Our Mission

EU-IPFF serves as the trusted resource for a united IPF patient voice by raising awareness, providing disease education, advancing care, and funding research.

Our Goals

1. Promoting access to accurate and unbiased information on IPF care
2. Advocating for the rights of IPF patients and carers and involvement of patients in key healthcare decisions
3. Improving access to treatment and services, including non-pharmacological treatment and medication across European countries
4. Facilitating information exchange and collaboration between European and international (I )PF patient associations
5. Fostering collaboratiion with scienHfic experts and medical societies
6. Supporting the establishment of patient associations in countries where there is no representation